Get started
Author

Zachary A. Cutshall

Observed names: Zachary A Cutshall, Zachary Cutshall
ORCID: 0000-0001-6391-3876
Observed ORCID: 0000-0001-6391-3876
OpenAlex ID: A5020638442
High ligation in adolescents: Is it enough?
2020 · Mark A. Taylor, Zachary A. Cutshall, et al. · Journal of Pediatric Surgery · 24
Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective
2023 · Minkyoung Yoo, Richard E Nelson, et al. · JNCI Journal of the National Cancer Institute · 23
PDF
Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective
2023 · Minkyoung Yoo, Richard E. Nelson, et al. · JCO Oncology Practice · 17
PDF
Recovery Curve for Patients With Pilon Fractures Using Patient-Reported Outcome Measurement Information System
2023 · Patrick J. Kellam, Zachary A. Cutshall, et al. · Foot & Ankle International · 7
PDF
Progression of symptomatic bilateral rotator cuff disease
2023 · Karch M. Smith, Christopher E. Clinker, et al. · JSES International · 3
PDF
Po-04-068 Collateral Vasospastic Response During Pulse Field Ablation of Cavotricuspid and Mitral Isthmus – Impact of Iv Nitroglycerin Pretreatment
2026 · Rutvi Amin, Aashish Katapadi, et al. · Heart Rhythm
26-a-18739-acc Use of Pulsed Field and Radiofrequency Ablation Adjacent to Cardiac Implantable Devices at the Cavotriscuspid Isthmus
2026 · Ahmed Elballat, Zachary Cutshall, et al. · Journal of the American College of Cardiology
Cost-effectiveness analysis (CEA) of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.
2023 · Manish Kohli, Maura Dougherty, et al. · Journal of Clinical Oncology
PDF
Cost-effectiveness analysis of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.
2023 · Manish Kohli, Maura Dougherty, et al. · Journal of Clinical Oncology
A VA Federal Supply Schedule (VAFSS)–based cost-effectiveness analysis of immunotherapy-tyrosine kinase inhibitor (IO-TKI) regimens and sunitinib in the treatment of metastatic renal cell carcinoma (mRCC).
2022 · Manish Kohli, Zachary Cutshall, et al. · Journal of Clinical Oncology
Works count: 10
Citation count: 74
H-index: 4
I10-index: 3
Year
Topic
Type